Nov. 7, 2012 | Vol. 29 No. 22
Hetero, Forest Reach Deal on Generic of Forest’s Bystolic
Hetero can launch a generic version of Forest Laboratories’ hypertension drug Bystolic three months prior to the expiration of Forest’s exclusivity on Dec. 17, 2021, or on the date it receives final ANDA approval from the agency, whichever is later under the terms of a proposed settlement.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.